Why Scientists Are Targeting IL-6 to Tame Inflammation: What a New Drug Trial Reveals About CRP and Heart Risk

Every news cycle about a new inflammation drug contains a phrase like "reduced inflammatory markers" or "lowered CRP." But unless you already understand the biology, those phrases float without meaning. What is the marker? What drives it? And why do researchers keep building drugs to target a protein called IL-6 when CRP is already available as a readout? The trial results announced this past weekend at the European Society of Cardiology Congress are a useful prompt to answer those questions, starting from the ground up.

The drug in question, pacibekitug, is an investigational human monoclonal antibody that targets the IL-6 ligand itself rather than its receptor. The company that developed it, Tourmaline Bio, was acquired by Novartis earlier this year for 1.4 billion dollars. The Phase 2 TRANQUILITY trial enrolled patients with chronic kidney disease who carry elevated inflammatory risk, a population in which systemic inflammation is both common and particularly damaging. Results presented on August 29, 2026 showed that the drug produced dose-dependent, sustained reductions in inflammatory biomarkers, with a safety profile characterized by few discontinuations and no clear dose-related safety signals, according to the ESC Congress press release and reporting by STAT News. A larger trial designed to test whether those biomarker reductions translate into fewer cardiovascular events is planned.

What IL-6 Is and Why It Matters

To understand what CRP measures, you first need to understand IL-6, because CRP does not arise on its own. When the body detects tissue damage, infection, or a threat signal, immune cells including macrophages and T cells release cytokines as chemical messengers. IL-6 is one of the most potent of these messengers for triggering what immunologists call the acute-phase response: a rapid, coordinated change in the behavior of the liver and other tissues designed to contain the perceived threat. The liver responds to IL-6 by dramatically ramping up production of proteins like CRP, which circulate in the blood and can be measured to gauge how active this response is.

In short-lived acute situations, this is entirely the point. You catch an infection, IL-6 rises, CRP rises, the response is marshaled, the threat is cleared, and both proteins return to baseline. The problem that has absorbed so much cardiovascular research in recent decades is what happens when the triggering signals do not go away. Visceral fat, for instance, acts as a reservoir of IL-6-producing cells. Damaged arterial walls attract macrophages that produce IL-6. Chronic stress, poor sleep, a high-glycemic diet, and smoking all maintain low-level IL-6 production. The result is a state of persistently elevated IL-6 and CRP that lacks the urgency of acute inflammation but carries a meaningful long-term cost.

What makes IL-6 particularly interesting to cardiovascular researchers is that it sits at a mechanistic crossroads. IL-6 does not merely produce CRP as a readout; it actively participates in the processes that drive atherosclerosis. It promotes the activation and recruitment of immune cells into arterial plaques, stimulates the liver to produce clotting factors, and drives the differentiation of cells toward a pro-inflammatory phenotype. Research by Harvard cardiologist Paul Ridker and colleagues laid out this upstream hierarchy clearly: CRP predicts cardiovascular risk in large population studies, but IL-6 helps cause the events that CRP reflects (Ridker, 2016). This distinction matters because a biomarker that predicts risk is useful for identifying who needs attention, while a driver that causes risk is a potential target for intervention.

The TRANQUILITY Trial in Context

Pacibekitug is not the first IL-6 pathway drug to show CRP reduction in a cardiovascular-adjacent population, and that history of evidence is what makes the new results meaningful. The clearest predecessor is ziltivekimab, tested in the RESCUE trial and published in The Lancet in 2021. In that Phase 2 double-blind trial, researchers enrolled 264 patients on hemodialysis, a group with notoriously high inflammatory burden, and randomized them to monthly doses of ziltivekimab or placebo. At twelve weeks, the highest ziltivekimab dose reduced high-sensitivity CRP by 77 percent from baseline, a dramatic effect accompanied by reductions in fibrinogen, serum amyloid A, and interleukin-6 itself (Ridker et al., 2021). That trial established proof-of-concept for this class of drugs in high-risk inflammatory populations, but the full cardiovascular outcomes trial for ziltivekimab stumbled in 2025 after its developer's partner decided not to continue, leaving Novartis's pacibekitug as the most advanced asset in the space with its outcomes trial now in design.

The TRANQUILITY data add a six-month safety and biomarker picture for pacibekitug specifically, and the sustained nature of the reductions is noteworthy. IL-6 inhibition is not new as a treatment for inflammatory conditions: tocilizumab and sarilumab, which block the IL-6 receptor rather than IL-6 itself, have been used for rheumatoid arthritis and other autoimmune conditions for years, and their efficacy in lowering CRP is well established. But applying these drugs to atherosclerotic cardiovascular disease has been more cautious, because the population is different and the benefit-to-risk calculation changes when patients do not have an existing inflammatory disorder requiring treatment. The TRANQUILITY results suggest pacibekitug can be given in this higher-risk general cardio-metabolic population with a manageable tolerability profile, which is the prerequisite for pursuing an outcomes trial.

A key biological question that the field is still working through is how much of the cardiovascular benefit from IL-6 inhibition comes from CRP reduction itself versus other downstream effects. Mendelian randomization studies, which use genetic variants as natural experiments to tease apart causation, have found that genetically lower IL-6 signaling is associated with reduced atherosclerotic cardiovascular disease risk, and that some of this relationship appears to be independent of CRP (Ridker, 2019). This means CRP is both a useful readout of what IL-6 is doing and an incomplete window into all the ways IL-6 shapes cardiovascular risk. For research purposes this distinction matters enormously; for someone monitoring their own general wellness, CRP remains the most practical and clinically familiar measure of systemic inflammatory tone.

What This Means for People Who Track Inflammation

Drug trials in high-risk patient populations might seem remote from everyday wellness decisions, but they carry clear implications for anyone interested in their own inflammatory health. The first is confirmatory: the fact that researchers believe they can improve long-term cardiovascular outcomes by lowering IL-6 and CRP speaks directly to why these markers are worth paying attention to in the first place. The science of inflammation and cardiovascular disease has spent decades accumulating evidence that elevated CRP, even at levels once considered "normal," is not a neutral finding. The JUPITER trial, for example, showed that people with elevated hsCRP but normal LDL cholesterol benefited from statin treatment in terms of cardiovascular events, which was a turning point in how the field thought about inflammation as a modifiable risk factor.

The second implication is about what CRP changes actually represent. If you use an at-home saliva CRP test and notice your level rise or fall over several weeks, what you are observing is a downstream readout of IL-6 activity, which in turn reflects the net balance of pro-inflammatory and anti-inflammatory signals in your body. A rise in CRP does not always mean something is wrong: it can reflect a recent workout, a minor illness, a period of poor sleep, or a dietary pattern that has temporarily increased inflammatory signaling. A sustained decline, on the other hand, often reflects a positive shift in one or more of those inputs. The point of tracking the biomarker over time is not to diagnose a condition but to observe the trend and, when it looks unusual or persistently elevated, to have a data-backed conversation with a healthcare provider.

The third implication is about the power of lifestyle, because that is where most people have their most immediate leverage. Drug researchers are targeting IL-6 with precision antibodies because lifestyle alone cannot always shift chronic inflammatory burden enough in people who already have end-stage kidney disease or established atherosclerosis. But in people without those conditions, the same IL-6 pathway responds to diet, exercise, sleep, and body composition in ways that are well-documented in the literature. Understanding that your lifestyle choices are working on the same molecular target that Novartis is spending 1.4 billion dollars to address with a drug is a useful reminder that inflammation is genuinely modifiable, and you have tools available right now.

Diet, Exercise, and the IL-6 Pathway

Anti-inflammatory dietary patterns, particularly the Mediterranean diet, have now been tested in enough randomized trials that a 2026 systematic review and meta-analysis could pool the results with confidence. A study published in Nutrition Reviews found that Mediterranean diet adherence produced significant reductions in circulating inflammatory markers including CRP across multiple populations (Keshani et al., 2026). The mechanisms plausibly involve several pathways: high polyphenol intake from olive oil, vegetables, and fruit reduces oxidative stress that triggers IL-6 release; omega-3 fatty acids from fish compete with omega-6 precursors of pro-inflammatory eicosanoids; and a high fiber intake supports a gut microbiome composition that limits bacterial products entering the bloodstream and stimulating immune cells.

Exercise has a nuanced relationship with IL-6 that is worth understanding correctly. During intense exercise, working muscles release IL-6 as a fuel-signaling molecule, which is why CRP can temporarily rise after a hard workout. This acute, exercise-induced IL-6 spike is distinct from the chronic low-grade IL-6 elevation seen in metabolic disease, and it is followed by a rebound in anti-inflammatory cytokines that produces a net benefit over time. Regular moderate exercise consistently reduces resting IL-6 and CRP in population studies, largely because it reduces visceral fat, improves insulin sensitivity, and improves the overall balance of immune signaling. The temporary rise in CRP after a workout resolves within 24 to 72 hours and should not be mistaken for a sign of harm.

Sleep is another lever that acts directly on IL-6. Human experimental studies in which volunteers are partially sleep-deprived for several days consistently show rising IL-6 and CRP compared with fully rested control periods. The mechanism involves the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis: poor sleep raises cortisol and catecholamines, both of which modulate immune cell behavior and cytokine production. Addressing sleep quality is therefore not a soft wellness recommendation; it is an intervention on the same signaling network that pharmaceutical companies are now trying to target with billion-dollar drugs.

What the Research Does Not Tell Us Yet

The TRANQUILITY trial has not yet reported outcomes in the cardiovascular events sense, and that distinction matters. Lowering a biomarker like CRP or IL-6 is a meaningful result, and the consistency of this effect across multiple drugs and trials is encouraging. But the field learned in the JUPITER trial era that a biomarker change does not always translate straightforwardly into event reduction, and that the patient population matters enormously. The next critical question for pacibekitug is whether the biomarker reductions seen in the TRANQUILITY Phase 2 will translate into fewer heart attacks, strokes, or other cardiovascular events in a larger Phase 3 trial. Novartis has indicated a heart outcomes study is planned, but those results are years away.

For people monitoring their own inflammation, this scientific gap is actually reassuring rather than discouraging. CRP is a well-validated marker of inflammatory burden, and the research supports caring about it without needing to wait for every therapeutic mechanism to be fully mapped. What the drug research does provide is a deeper biological rationale for why CRP matters: it is not a random number, but a downstream readout of an inflammatory signaling cascade that scientists are now confident enough in to invest enormous resources in targeting. Tracking it over time and discussing persistent changes with a healthcare provider is consistent with the best current understanding of how inflammation and cardiovascular risk interact.

Sources

• European Society of Cardiology. "Sustained reductions in inflammatory markers seen with novel antibody drug." ESC Congress 2026 press release, August 2026. escardio.org
• Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060-2069. pubmed.ncbi.nlm.nih.gov/34015342
• Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circulation Research. 2016;118(1):145-156. pubmed.ncbi.nlm.nih.gov/26837745
• Ridker PM. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Circulation Research. 2019;124(3):437-450. pubmed.ncbi.nlm.nih.gov/30702995
• Keshani M, Rafiee S, Heidari H, et al. Mediterranean Diet Reduces Inflammation in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Nutrition Reviews. 2026. pubmed.ncbi.nlm.nih.gov/41211687

Frequently Asked Questions

What is IL-6 and how does it relate to CRP?

IL-6 (interleukin-6) is a cytokine, a signaling protein the immune system uses to coordinate inflammation. One of its key roles is triggering the liver to produce C-reactive protein (CRP), which is why CRP is so useful as a blood marker of inflammation. When IL-6 rises, CRP rises with it, and both go up in conditions involving chronic inflammation including atherosclerotic cardiovascular disease.

What did the TRANQUILITY trial find about pacibekitug?

The Phase 2 TRANQUILITY trial, results of which were presented at ESC Congress 2026 on August 29, 2026, found that pacibekitug, an investigational antibody targeting the IL-6 ligand, produced sustained reductions in inflammatory biomarkers over six months in patients with chronic kidney disease at high inflammatory risk. The drug was well tolerated, with discontinuations in fewer than 2 percent of participants, and higher doses produced greater reductions in inflammatory markers.

Can tracking CRP help people monitor cardiovascular inflammation?

CRP is one of the most-studied biomarkers of systemic inflammation and is routinely used in cardiovascular research to measure inflammatory burden. While CRP is a general wellness marker rather than a diagnostic test, persistently elevated levels can be a useful signal to bring to a healthcare provider, especially for people interested in tracking their overall inflammatory tone over time and observing how lifestyle changes affect their numbers.

Can lifestyle changes lower IL-6 and CRP?

Yes. Anti-inflammatory dietary patterns, particularly the Mediterranean diet, have been shown in multiple randomized controlled trials to reduce circulating inflammatory markers including CRP. Regular physical activity, adequate sleep, stress management, and avoiding smoking also consistently reduce systemic inflammation. These lifestyle factors work upstream of the same IL-6/CRP pathway that drug researchers are now targeting with precision therapies.